Not finding it? Sign in to also search OpenAlex live.
-
Pan-cancer analysis of cholesterol metabolism reveals the uptake as a modulator of tumor immune features and of the KRAS pathway2026 Cellular Oncology article Biochemistry, Genetics and Molecular Biology Cancer, Lipids, and Metabolism Open access
Ana Luísa Machado, Ana Pinto, Verónica Fernandes, Luísa Pereira, Jessica P Roelands, Jorge Gonçalves, +3 more
1citations -
KEYMAKER-U01J: Calderasib plus pembrolizumab with or without cetuximab as first-line treatment for advanced or metastatic nonsquamous non–small-cell lung cancer (NSCLC) with KRAS G12C mutations.
Qing Zhou, Daniel Almquist, B K Cho, Egbert Frederik Smit, Christian Caglevic, Ilkka Liikanen, +13 more
0citations -
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer2020 British Journal of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Ferry A.L.M. Eskens, Sanne C.F.A. Huijberts, Filip De Vos, Martijn P. Lolkema, +11 more
57citations -
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.2020 Journal of Clinical Oncology conference-abstract Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways
Sanne C.F.A. Huijberts, Emilie M.J. van Brummelen, Carla M.L. van Herpen, Ingrid M.E. Desar, Frans L. Opdam, Robin M.J.M. van Geel, +9 more
3citations -
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming2022 Journal of Experimental & Clinical Cancer Research article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access
Leticia Colyn, Gloria Álvarez‐Sola, Maria Ujue Latasa, Iker Uriarte, José M. Herranz, María Arechederra, +28 more
35citations -
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer2020 Cancer Chemotherapy and Pharmacology article Medicine Colorectal Cancer Treatments and Studies Open access
Sanne C.F.A. Huijberts, Robin M.J.M. van Geel, Emilie M.J. van Brummelen, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, +8 more
46citations -
Response: Commentary: An In Silico–In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients2021 Frontiers in Immunology editorial Biochemistry, Genetics and Molecular Biology vaccines and immunoinformatics approaches Open access cited by 2 patents
Michele Mishto, Guillermo Rodriguez-Hernandez, Jacques Neefjes, Henning Urlaub, Juliane Liepe
10citations -
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up2023 Annals of Oncology article Medicine Lung Cancer Treatments and Mutations Open access cited by 1 patent
Lizza E.L. Hendriks, Keith M. Kerr, Jessica Menis, Tony S.K. Mok, Ursula Nestle, Antonio Passaro, +6 more
854citations